ZYLA LIFE SCIENCES (FKA EGALET CORPORATION) for ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Prescription drug abuse policy issues Provisions related to abuse-deterrent opioid formulary placement Provisions related to abuse-deterrent opioid coverage and access in Medicare
| Lobbyist | Covered position, as disclosed |
|---|---|
| CARA D MOON | — |
Health Issues HCR
Prescription drug abuse and misuse policy issues H.R. 2335 (114th Congress), the Stop Tampering of Prescription Pills Act: provisions related to approval of abuse-deterrent opioids H.R. 5127 (114th Congress), the Curb Opioid Misuse by Advancing Technology (COMBAT) Act: provisions related to encouraging the development of abuse-deterrent technology H.R. 4482, the Opioid Abuse Deterrence, Research, and Recovery Act: provisions related to the development of abuse-deterrent opioids Abuse-deterrent opioid policy issues Pain therapy access policy issues
| Lobbyist | Covered position, as disclosed |
|---|---|
| CARA D MOON | — |
Alcohol and Drug Abuse ALC
S. 524 (114th Congress): Provisions related to opioid treatment and abuse
| Lobbyist | Covered position, as disclosed |
|---|---|
| CARA D MOON | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.